Boston Trust Walden Corp Sells 7,252 Shares of Stryker Corporation (NYSE:SYK)

Boston Trust Walden Corp reduced its stake in Stryker Corporation (NYSE:SYK) by 2.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 320,968 shares of the medical technology company’s stock after selling 7,252 shares during the period. Stryker makes up approximately 0.9% of Boston Trust Walden Corp’s holdings, making the stock its 22nd largest holding. Boston Trust Walden Corp owned approximately 0.08% of Stryker worth $119,480,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. J. W. Coons Advisors LLC grew its stake in shares of Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after purchasing an additional 26 shares during the period. Mascoma Wealth Management LLC increased its holdings in Stryker by 22.7% during the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock valued at $53,000 after purchasing an additional 27 shares in the last quarter. Lindbrook Capital LLC increased its holdings in Stryker by 2.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock valued at $507,000 after purchasing an additional 28 shares in the last quarter. Capital & Planning LLC increased its holdings in Stryker by 3.6% during the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after purchasing an additional 29 shares in the last quarter. Finally, United Community Bank increased its holdings in Stryker by 3.4% during the 4th quarter. United Community Bank now owns 904 shares of the medical technology company’s stock valued at $325,000 after purchasing an additional 30 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

SYK stock opened at $373.22 on Thursday. The business’s fifty day moving average is $373.92 and its 200-day moving average is $375.52. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. The company has a market cap of $142.45 billion, a P/E ratio of 50.43, a price-to-earnings-growth ratio of 2.82 and a beta of 0.91. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.50 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Monday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 45.41%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on SYK shares. Citigroup reaffirmed a “buy” rating and set a $455.00 price target (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. BTIG Research set a $403.00 price target on Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Friday, March 21st. Finally, The Goldman Sachs Group set a $422.00 price target on Stryker in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $427.30.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.